C7287

Sigma-Aldrich

Canrenoic acid potassium salt

powder

Synonym(s):
Potassium canrenoate, 17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid
Linear Formula:
C22H30O4K
CAS Number:
Molecular Weight:
397.57
EC Number:
MDL number:
PubChem Substance ID:
NACRES:
NA.77
Pricing and availability is not currently available.

form

powder

Quality Level

color

light yellow to tan

SMILES string

[K].[H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@@]3(O)CCC(O)=O)[C@]1([H])C=CC4=CC(=O)CC[C@]24C

InChI

1S/C22H30O4.K.H/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);;/t16-,17+,18+,20+,21+,22-;;/m1../s1

InChI key

YLXFIHIYNGPPSF-HUHWECDNSA-N

Application

Canrenoic acid potassium salt has been used as a human uridine 5′-diphospho (UDP)-glucuronosyltransferase inhibitor to study its effects on trifluoperazine (TFP) substrate selectivity. It has also been used to study its effects on the formation of aldosterone 18-glucuronide (ALDO 18β-G) in recombinant UDP-Glucuronosyltransferase-2B7 (UGT2B7), human liver (HLM) and human kidney cortical (HKCM) microsomes.

Packaging

5 g in poly bottle

Biochem/physiol Actions

Competitive aldosterone receptor antagonist. Potassium canrenoate reduces the effects of aldosterone-induced increases in blood pressure and in cardiovascular fibrosis in animals with high sodium intake. It is used clinically for its anti-fibrotic effects. At higher doses it is genotoxic to liver and increases tumor incidence in rodent models.

Quality

Aqueous solutions may contain some insoluble material.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Certificate of Analysis
Certificate of Origin
Farzin Beygui et al.
American heart journal, 160(4), 642-648 (2010-10-12)
Aldosterone is at its highest levels at presentation for acute myocardial infarction (AMI). High aldosterone levels are predictive of poor outcome regardless of heart failure. Angiotensin-converting enzyme inhibitors have delayed partial and temporary effects on aldosterone levels. We hypothesize that...
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone)?probes? for human UDP-glucuronosyltransferases
Uchaipichat V, et al.
Drug Metabolism and Disposition, 34(3), 449-456 (2006)
P Angeli et al.
Gut, 59(1), 98-104 (2009-07-03)
The aim of the study was to compare sequential versus combined diuretic therapy in patients with cirrhosis, moderate ascites and without renal failure. One hundred patients were randomly assigned to the two diuretic treatments. The sequential treatment provided potassium canrenoate...
Melissa Lingis et al.
American journal of physiology. Endocrinology and metabolism, 300(3), E592-E599 (2011-01-06)
During pregnancy, plasma ACTH and cortisol are chronically increased; this appears to occur through a reset of hypothalamo-pituitary-adrenal (HPA) activity. We have hypothesized that differences in mineralocorticoid receptor activity in pregnancy may alter feedback inhibition of the HPA axis. We...
Katharina Schmidt et al.
European heart journal, 31(13), 1655-1662 (2009-12-24)
Pre-treatment with mineralocorticoid receptor (MR) antagonists is reported to reduce myocardial infarct size from ischaemia/reperfusion. Here, we tested whether the MR antagonists potassium canrenoate and eplerenone could protect in the more clinically relevant schedule of administration at the end of...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.